Paloma Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-55,200
| Closed | -$2.29M | – | 1185 |
|
|
2024
Q2 | $2.29M | Buy |
+55,200
| New | +$2.47M | 0.06% | 320 |
|
|
2024
Q1 | – | Sell |
-16,200
| Closed | -$831K | – | 795 |
|
|
2023
Q4 | $831K | Sell |
16,200
-74,800
| -82% | -$3.93M | 0.03% | 451 |
|
|
2023
Q3 | $5.28M | Sell |
91,000
-21,800
| -19% | -$1.34M | 0.18% | 98 |
|
|
2023
Q2 | $7.21M | Buy |
112,800
+57,500
| +104% | +$3.86M | 0.26% | 62 |
|
|
2023
Q1 | $3.83M | Sell |
55,300
-18,100
| -25% | -$1.28M | 0.13% | 129 |
|
|
2022
Q4 | $5.28M | Buy |
+73,400
| New | +$5.53M | 0.24% | 63 |
|
|
2022
Q3 | – | Sell |
-25,100
| Closed | -$1.93M | – | 1028 |
|
|
2022
Q2 | $1.93M | Buy |
+25,100
| New | +$1.91M | 0.07% | 274 |
|
|
2022
Q1 | – | Sell |
-393,300
| Closed | -$24.5M | – | 1794 |
|
|
2021
Q4 | $24.5M | Buy |
+393,300
| New | +$23.1M | 0.36% | 20 |
|
|
2021
Q2 | – | Sell |
-91,400
| Closed | -$5.77M | – | 1802 |
|
|
2021
Q1 | $5.77M | Buy |
91,400
+90,500
| +10,056% | +$5.63M | 0.12% | 131 |
|
|
2020
Q4 | $55K | Sell |
900
-170,000
| -99% | -$10.5M | ﹤0.01% | 1554 |
|
|
2020
Q3 | $10.3M | Buy |
170,900
+79,000
| +86% | +$4.75M | 0.26% | 57 |
|
|
2020
Q2 | $5.4M | Buy |
91,900
+51,700
| +129% | +$3.09M | 0.09% | 272 |
|
|
2020
Q1 | $2.24M | Buy |
+40,200
| New | +$2.46M | 0.13% | 118 |
|
|
2019
Q4 | – | Sell |
-20,800
| Closed | -$1.05M | – | 2159 |
|
|
2019
Q3 | $1.05M | Buy |
+20,800
| New | +$978K | 0.02% | 712 |
|
|
2018
Q3 | – | Sell |
-68,800
| Closed | -$3.81M | – | 1563 |
|
|
2018
Q2 | $3.81M | Buy |
+68,800
| New | +$3.72M | 0.07% | 233 |
|
|
2018
Q1 | – | Sell |
-5,000
| Closed | -$306K | – | 1952 |
|
|
2017
Q4 | $306K | Buy |
+5,000
| New | +$313K | ﹤0.01% | 1540 |
|
|
2017
Q3 | – | Sell |
-125,000
| Closed | -$6.96M | – | 2104 |
|
|
2017
Q2 | $6.96M | Sell |
125,000
-11,400
| -8% | -$620K | 0.08% | 229 |
|
|
2017
Q1 | $7.42M | Buy |
+136,400
| New | +$7.48M | 0.09% | 179 |
|
|
2016
Q4 | – | Sell |
-24,800
| Closed | -$1.34M | – | 1970 |
|
|
2016
Q3 | $1.34M | Sell |
24,800
-789,200
| -97% | -$50.7M | 0.02% | 791 |
|
|
2016
Q2 | $59.9M | Buy |
814,000
+708,300
| +670% | +$50M | 0.66% | 15 |
|
|
2016
Q1 | $6.75M | Buy |
105,700
+89,700
| +561% | +$5.66M | 0.11% | 120 |
|
|
2015
Q4 | $1.1M | Buy |
16,000
+8,000
| +100% | +$529K | 0.03% | 622 |
|
|
2015
Q3 | $474K | Sell |
8,000
-569,300
| -99% | -$36.1M | 0.01% | 1053 |
|
|
2015
Q2 | $38.4M | Buy |
+577,300
| New | +$38M | 0.74% | 19 |
|
Other funds holding BMY
Paloma Partners's BMY Position: Q3 2024 in Review
Paloma Partners sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 31,190 shares — an estimated $1.3M sold.
Paloma Partners first reported a position in BMY in Q2 2013 and held it in 34 quarters. The position peaked at $14.6M in Q2 2020. 2,258 funds tracked by Wall St. Rank hold BMY as of Q3 2024.
- Paloma Partners reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
- Paloma Partners sold 31,190 Bristol-Myers Squibb shares in Q3 2024, an estimated $1.3M.
- Paloma Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 34 quarters.
- Paloma Partners's Bristol-Myers Squibb position peaked at $14.6M in Q2 2020.
- 2,258 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.
Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.